Navigation Links
Prospective study finds many children with retinoblastoma can safely forego adjuvant chemotherapy
Date:3/4/2013

In this News Digest:

  • Summary of a study being published online March 4, 2013 in the Journal of Clinical Oncology, reporting that in certain children with retinoblastoma, adjuvant chemotherapy can be avoided, without risking disease worsening or relapse.
  • The findings will help decision-making about adjuvant treatment and therapy selection for patients with low- , intermediate-, and high-risk retinoblastoma affecting only one eye
  • Quote for attribution to ZoAnn Eckert Dreyer, MD, American Society of Clinical Oncology Cancer Communications Committee member and pediatric cancers expert
  • Links to additional resources on Cancer.Net, ASCO's cancer information Website

New results from a prospective clinical trial conducted in France show that children with low-risk retinoblastoma do not need postoperative (adjuvant) chemotherapy to prevent disease recurrence or metastasis; the results also suggest that certain patients with intermediate-risk disease can receive less aggressive adjuvant treatment, or perhaps forego it altogether. Avoiding chemotherapy spares patients from treatment side effects and long-term health risks, such as cardiovascular disease and development of a second cancer.

Retinoblastoma is a rare form of cancer, accounting for three percent of all cancers diagnosed in children under the age of 15. An estimated 300 cases of retinoblastoma will be diagnosed in the United States this year, most before the age of five years. The tumor begins in the retina, a thin layer of nerve tissue that coats the back of the eye.

About two thirds of children with retinoblastoma have unilateral disease, meaning that only one eye is affected by the tumor. In developed countries, this type of disease is typically detected around two years of age. More than 95 percent of such patients are cured by surgical removal or the affected eyeball, with eyesight preserved in the other eye. However, some patients remain at risk of disease spreading and recurrence.

To estimate the risk of disease recurrence and metastasis, doctors examine the surgically removed eye under a microscope and classify the tumor as either low-, intermediate-, or high-risk. All patients whose tumors are considered high-risk receive intensive postoperative chemotherapy and radiation therapy. There is no general consensus, however, on the need for adjuvant therapy and the optimal treatment approach for patients in the other two risk categories. Therefore, protocols for adjuvant chemotherapy use in these patient groups have varied widely.

"Our study confirms that it is not necessary to give adjuvant treatment to many children with unilateral retinoblastoma," said lead study author Isabelle Aerts, MD, a pediatric oncologist at Institut Curie in Paris, France. "I think that our results will help establish the standard of care for such patients, reducing variations in postoperative chemotherapy protocols."

In the present study, 123 patients with unilateral, non-hereditary retinoblastoma were assigned to one of three risk groups according to previously established criteria. The median age at the time of eye removal surgery was 23 months. The 70 patients with low-risk disease received no postoperative chemotherapy; the 52 patients with intermediate-risk disease received four courses of adjuvant chemotherapy (etoposide, carboplatin, vincristine, cyclophosphamide), and the only patient with high-risk disease received six courses of high-dose adjuvant therapy (etoposide, carboplatin, thiotepa, vincristine, and cyclophosphamide).

At a median follow-up period of 71 months, all patients were alive. None of the patients experienced disease worsening, relapse, distant metastasis or secondary cancers. The adjuvant chemotherapy was safe overall. These data confirm that the specific regimens administered in this study, which are already being used around the world, are very effective and safe.

The excellent outcomes observed in this study confirm it is safe for patients with low-risk disease to go without adjuvant therapy and suggest that it may be safe to reduce the intensity of or even eliminate adjuvant chemotherapy in some patients with intermediate-risk disease, specifically those with a risk feature known as isolated choroidal invasionspreading of tumor cells to the layer of blood vessels and connective tissue at the back of the eye. However, more research is needed to establish clinical criteria for identifying such patients. As all patients were alive at the end of the follow up period, it is not clear whether adjuvant treatment played a vital role, or if surgery would have been sufficient.

Aerts and her research team have recently launched a new study to confirm these results and also determine if treatment could be reduced in some patients in the intermediate-risk category. In this ongoing study, patients with intermediate-risk disease and isolated choroidal invasion are being treated with only two cycles of adjuvant chemotherapy.

ASCO Perspective

ZoAnn Eckert Dreyer, MD, ASCO Cancer Communications Committee member and pediatric cancers expert

"While this study does not include a novel therapy, it demonstrates that with improved, refined risk stratification, it may be possible to reduce chemotherapy in some patient groups particularly those with intermediate-risk disease. Physicians and parents can be reassured that many children can go without aggressive chemotherapy and be spared from its long- and short-term effects. This will potentially result in a change in the standard of care for these patients."


'/>"/>

Contact: Nicole Racadag
nicole.racadag@asco.org
571-483-1354
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. Certain Sleep Aids May Raise Hip Fracture Risk in Nursing Homes: Study
2. Daily-use HIV prevention approaches prove ineffective among women in NIH study
3. Study of tenofovir vaginal gel shows daily dosing ineffective due to lack of adherence
4. Pregnancy Boosts Size of Womens Feet, Study Finds
5. Unhealthy drinking widespread around the world, CAMH study shows
6. Vanderbilt study finds maternal diet important predictor of severity for infant RSV
7. Bel Marra Health Reports on a New Study: Software Originally Used for Star Gazing Now Being Used to Analyze Breast Cancer Tissue
8. Growing Old in Suburbia: A Challenge for our Nation’s Elderly - A North Shore-LIJ Health System Study
9. Kids, Seniors Prone to MRSA Infections Depending on Season: Study
10. Study confirms safety of colonoscopy
11. Cancer doesnt change young girls desire to have children, Moffitt Cancer Center study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology: